{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:56:25Z","timestamp":1780563385518,"version":"3.54.1"},"reference-count":7,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,3,4]],"date-time":"2004-03-04T00:00:00Z","timestamp":1078358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We report on a patient who developed orofacial dyskinesia 3 days after starting ofloxacin treatment. The association of orofacial dyskinesia with other fluoroquinolone antibiotics has been reported rarely, chiefly in the elderly with impaired renal or hepatic function or in overdosed patients. It has been ascribed to interference with GABA\u2010ergic neurotransmission. \u00a9 2004 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.20053","type":"journal-article","created":{"date-parts":[[2004,3,25]],"date-time":"2004-03-25T12:34:22Z","timestamp":1080218062000},"page":"731-732","source":"Crossref","is-referenced-by-count":11,"title":["Reversible orofacial dyskinesia after ofloxacin treatment"],"prefix":"10.1002","volume":"19","author":[{"given":"Jan L.","family":"De Bleecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle L.","family":"Vervaet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,3,4]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013373435"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967014"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/515104"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000205"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00900953"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.12968\/hosp.2000.61.2.2404"},{"key":"e_1_2_4_8_2","first-page":"518","article-title":"Extrapyramidal side\u2010effects secondary to venlafaxine","volume":"33","author":"Tzallas PJ","year":"1995","journal-title":"J Toxicol Clin Toxicol"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20053","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.20053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:28:40Z","timestamp":1760966920000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.20053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,4]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1002\/mds.20053"],"URL":"https:\/\/doi.org\/10.1002\/mds.20053","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,4]]}}}